Newsstand | Aplastic Anemia and MDS International Foundation

Newsstand

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

The MDS Clinical Research Consortium

Originally Published: 10/17/2018
The MDS Clinical Research Consortium (MDS- CRC) is an unprecedented, six-institution group designed to undertake unique studies and trials to advance treatments and improve outcomes for patients with myelodysplastic syndromes (MDS). Member institutions are six academic medical centers serving a high volume of MDS patients: Cleveland Clinic Taussig Cancer Institute Dana-Farber Cancer Institute H. Lee Moffitt Cancer Center and Research Institute  MD Anderson Cancer Center Weill Medical College of Cornell University Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins The consortium is...

What is Flow Cytometry?

Originally Published: 10/10/2018
Flow cytometry is the “go-to” test for diagnosing PNH.  PNH happens because of a change (mutation) in the PIG-A gene of a subset of stem cells in bone marrow. This gene controls the creation of substance that helps certain proteins to stick to the surface of blood cells. Therefore, any blood cells created by this mutated bone marrow stem cell are abnormal because they can be destroyed by the complement system, which is a component of our immune system. Using light scattering techniques and fluorescence, flow cytometry can show your doctor if any proteins are missing from the surface of blood...

Combinations May Confer Benefit in MDS Management

Originally Published: 10/10/2018
Although investigational agents are showing promise for patients with low-risk myelodysplastic syndrome (MDS), physicians are still seeking combinations that will enhance responses for patients with high-risk disease, explained Mikkael A. Sekeres, MD.

Promising Results of a Phase 1/2 Clinical Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia

Originally Published: 10/09/2018
MDS/MPN (myelodysplastic syndromes/myeloproliferative neoplasms) is a disease of the blood and bone marrow with features of both MDS and MPN.  The most common form is CMML, or chronic myelomonocitic leukemia.  In CMML, abnormal blood cells (myeloblasts and myelocytes) accumulate in the bone marrow and other organs, and they interfere with the production of healthy blood cells.  This study led by Dr. Eric Padron through the MDS Clinical Research Consortium sites showed promising results for a new CMML treatment.   This Phase I/II study was conducted by Dr. Eric Padron of the H. Lee Moffitt...

Expert Recaps Advances in AML

Originally Published: 09/26/2018
Now that physicians have access to novel therapies for patients with acute myeloid leukemia (AML) following a 30-year gap in therapeutic development, physicians must now aim to understand their optimal placement in treatment, explained Rami S. Komrokji, MD. “The landscape is changing; it’s an exciting time,” said Komrokji.

Multiple Studies Help Define New Biomarkers for Myelodysplastic Syndromes

Originally Published: 09/11/2018
According to a story from Medpage Today, three recent research studies have managed to reveal new biomarkers for myelodysplastic syndromes. Biomarkers are a crucial factor for understanding a medical condition or disease. They can serve as critical diagnostic tools when signs and symptoms are too vague for doctors to make an accurate determination.In addition, biomarkers can help doctors make critical decisions about how to administer care.

Dr. Komrokji on the Changing Landscape of AML

Originally Published: 09/10/2018
Rami S. Komrokji, MD, principal investigator, MDS Research Consortium, Aplastic Anemia and MDS International Foundation, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses the changing landscape of acute myeloid leukemia (AML).  (video format)

Leukemia Research: Acute Myeloid Leukemia Researcher targets frequent culprit in blood cancers

Originally Published: 09/04/2018
Ramesh Balusu, Ph.D., one of our researchers at The University of Kansas Cancer Center, is working to uncover what happens behind the scenes leading to the development of certain types of blood cancers like acute myeloid leukemia. 

CHIP – A Promising Genetic Discovery for MDS, AML and Cardiovascular Disease

Originally Published: 08/30/2018
Thanks to recent advances in genetic analysis techniques, scientists studying how genetic mutations impact the progression of bone marrow failure have discovered how these mutations may also affect cardiovascular disease.  An example of this is new research that has shown how a buildup of mutated stem cells in the bone marrow may be a risk factor not only for hematologic malignancy but also heart disease. This condition is known as clonal hematopoiesis of indeterminate potential, or CHIP. The key word in understanding the significance of CHIP is “indeterminate,” because researchers are still...

Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation

Originally Published: 08/30/2018
This multicenter study, which began in 2013, was led by Dr. Eytan Stein at Memorial Sloan Kettering Cancer Center in New York, NY. Its purpose was to evaluate the safety and efficacy of orally administered AG-221 (Enasidenib) in subjects with advanced Acute Myeloid Leukemia (AML) that harbor an IDH2 mutation. As a result of this phase I/II study, and Celgene’s request for priority review status, the FDA approved of AG-221 in August, 2017 for patients with relapse and/or refractory AML with an IDH2 mutation. During the study, researchers discovered that AG-221 also had a positive effect on...